These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 9430587)

  • 1. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.
    Arap W; Pasqualini R; Ruoslahti E
    Science; 1998 Jan; 279(5349):377-80. PubMed ID: 9430587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-guided cancer drugs show promise in mice.
    Barinaga M
    Science; 1998 Jan; 279(5349):323-4. PubMed ID: 9454325
    [No Abstract]   [Full Text] [Related]  

  • 3. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
    van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
    Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model.
    Kim JW; Lee HS
    Int J Mol Med; 2004 Oct; 14(4):529-35. PubMed ID: 15375578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-specific prodrug activation by antibody-beta-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis.
    Meyer DL; Law KL; Payne JK; Mikolajczyk SD; Zarrinmayeh H; Jungheim LN; Kling JK; Shepherd TA; Starling JJ
    Bioconjug Chem; 1995; 6(4):440-6. PubMed ID: 7578364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.
    Du B; Han H; Wang Z; Kuang L; Wang L; Yu L; Wu M; Zhou Z; Qian M
    Mol Cancer Res; 2010 Feb; 8(2):135-44. PubMed ID: 20145035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
    Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
    Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular targeting with phage peptide libraries.
    Pasqualini R
    Q J Nucl Med; 1999 Jun; 43(2):159-62. PubMed ID: 10429511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the activity of doxorubicin analogues using colony-forming assays and human xenografts.
    Taetle R; Howell SB; Giuliani FC; Koziol J; Koessler A
    Cancer; 1982 Oct; 50(8):1455-61. PubMed ID: 6956427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha v integrins as receptors for tumor targeting by circulating ligands.
    Pasqualini R; Koivunen E; Ruoslahti E
    Nat Biotechnol; 1997 Jun; 15(6):542-6. PubMed ID: 9181576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
    Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
    J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foot-and-mouth disease virus-like particles as integrin-based drug delivery system achieve targeting anti-tumor efficacy.
    Yan D; Teng Z; Sun S; Jiang S; Dong H; Gao Y; Wei Y; Qin W; Liu X; Yin H; Guo H
    Nanomedicine; 2017 Apr; 13(3):1061-1070. PubMed ID: 27993721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomalized oligopeptides in cancer therapy.
    Asai T; Oku N
    Methods Enzymol; 2005; 391():163-76. PubMed ID: 15721380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. iRGD as a tumor‑penetrating peptide for cancer therapy (Review).
    Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J
    Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor.
    Li J; Ji J; Holmes LM; Burgin KE; Barton LB; Yu X; Wagner TE; Wei Y
    Cancer Gene Ther; 2004 May; 11(5):363-70. PubMed ID: 15044960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine).
    Niidome T; Yamauchi H; Takahashi K; Naoyama K; Watanabe K; Mori T; Katayama Y
    J Biomater Sci Polym Ed; 2014; 25(13):1362-73. PubMed ID: 25040893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
    Lee TY; Lin CT; Kuo SY; Chang DK; Wu HC
    Cancer Res; 2007 Nov; 67(22):10958-65. PubMed ID: 18006841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Development of Polysaccharide-Doxorubicin-Peptide Bioconjugates for Dual Synergistic Effects of Integrin-Targeted and Cell-Penetrating Peptides for Cancer Chemotherapy.
    Mansur AAP; Carvalho SM; Lobato ZIP; Leite MF; Cunha ADS; Mansur HS
    Bioconjug Chem; 2018 Jun; 29(6):1973-2000. PubMed ID: 29790738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells.
    Hölig P; Bach M; Völkel T; Nahde T; Hoffmann S; Müller R; Kontermann RE
    Protein Eng Des Sel; 2004 May; 17(5):433-41. PubMed ID: 15235124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.